{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:01:58Z","timestamp":1793671318546,"version":"4.5.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005923","name":"International Association for the Study of Lung Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jtho.2025.07.009","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T19:32:15Z","timestamp":1751916735000},"page":"1594-1614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7685-051X","authenticated-orcid":false,"given":"Mihaela","family":"Aldea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K.","family":"Rotow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Arcila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hatton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette","family":"Sholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tagliamento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Radonic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt A.","family":"Schalper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja C.","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Manochakian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Sound","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Linardou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Greystoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Saqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Lantuejoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Nevins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murry","family":"Wynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiama","family":"Waqar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Yatabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Tavora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred R.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Denninghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha B.","family":"Leighl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Dacic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranshu","family":"Mohindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Lopez-Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2025.07.009_bib1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib2","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib3","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41571-023-00824-4","article-title":"Molecular tumour boards - current and future considerations for precision oncology","volume":"20","author":"Tsimberidou","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib4","article-title":"Comprehensive review on the clinical impact of next-generation sequencing tests for the management of advanced cancer","volume":"7","author":"Gibbs","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib5","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-020-18613-3","article-title":"Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy","volume":"11","author":"Kato","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.07.009_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.annonc.2023.01.008","article-title":"Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2025.07.009_bib8","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","article-title":"Overcoming resistance to tumor-targeted and immune-targeted therapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.07.009_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41698-024-00518-9","article-title":"EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers","volume":"8","author":"Tagliamento","year":"2024","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib10","article-title":"Oncologist confidence in genomic testing and implications for using multimarker tumor panel tests in practice","volume":"4","author":"de Moor","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib11","article-title":"Use of next-generation sequencing tests to guide cancer treatment: results from a nationally representative survey of oncologists in the United States","volume":"2","author":"Freedman","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib12","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jtho.2020.05.002","article-title":"The International Association for the Study of Lung Cancer global survey on molecular testing in lung cancer","volume":"15","author":"Smeltzer","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000398","article-title":"Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer","volume":"3","author":"Rolfo","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2025.07.009_bib14","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.trecan.2020.05.008","article-title":"Molecular tumor boards in clinical practice","volume":"6","author":"Luchini","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jtho.2025.07.009_bib15","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/annonc\/mdx528","article-title":"Molecular Tumor Boards: current practice and future needs","volume":"28","author":"van der Velden","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103966","article-title":"Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy","volume":"9","author":"de Jager","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2025.07.009_bib17","article-title":"Molecular tumor board Review and improved overall survival in non-small-cell lung cancer","volume":"5","author":"Huang","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib18","article-title":"Real-world data from a molecular tumor board: improved outcomes in breast and gynecologic cancers patients with precision medicine","volume":"6","author":"Charo","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib19","article-title":"The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours","volume":"36","author":"El Helali","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.jtho.2025.07.009_bib20","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2023.06.011","article-title":"ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2022.09.005","article-title":"Access and quality of biomarker testing for precision oncology in Europe","volume":"176","author":"Normanno","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2025.07.009_bib22","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jtho.2024.09.029","article-title":"OA03.03 the 2024 International Association for the Study of Lung Cancer (IASLC) global survey on biomarker testing","volume":"19","author":"Smeltzer","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib23","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.annonc.2025.02.009","article-title":"ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice","volume":"36","author":"Westphalen","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: how to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"key":"10.1016\/j.jtho.2025.07.009_bib25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jtho.2025.07.009_bib26","article-title":"Personalized therapy in a patient with EGFR-mutated NSCLC developing sequential CCDC6-RET fusion and BRAF V600E mutation as bypass resistance mechanisms","volume":"6","author":"Marinello","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2025.07.009_bib27","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.07.009_bib28","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1158\/1078-0432.CCR-22-2189","article-title":"Osimertinib and Selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers","volume":"29","author":"Rotow","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.07.009_bib29","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.trecan.2019.09.008","article-title":"Receptor tyrosine kinase fusions as an actionable resistance mechanism to EGFR TKIs in EGFR-mutant non-small-cell lung cancer","volume":"5","author":"Zhu","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jtho.2025.07.009_bib30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5858\/arpa.2023-0419-CP","article-title":"Laboratory considerations for releasing next-generation sequencing data to patients","volume":"149","author":"Moyer","year":"2025","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2025.07.009_bib31","article-title":"Optimizing a patient-centered report of somatic and germline genetic test results","volume":"9","author":"Anandarajah","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib32","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s43018-022-00378-x","article-title":"Author Correction: the Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology","volume":"3","author":"Tamborero","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jtho.2025.07.009_bib33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.5694\/mja18.00227","article-title":"Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers","volume":"209","author":"Thavaneswaran","year":"2018","journal-title":"Med J Aust"},{"key":"10.1016\/j.jtho.2025.07.009_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41698-022-00312-5","article-title":"MatchMiner: an open-source platform for cancer precision medicine","volume":"6","author":"Klein","year":"2022","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib35","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","volume":"13","author":"Lindeman","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the association for molecular pathology and College of American Pathologists","volume":"19","author":"Jennings","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jtho.2025.07.009_bib38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13059-024-03294-8","article-title":"Evaluation of somatic copy number variation detection by NGS technologies and bioinformatics tools on a hyper-diploid cancer genome","volume":"25","author":"Masood","year":"2024","journal-title":"Genome Biol"},{"key":"10.1016\/j.jtho.2025.07.009_bib39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41698-020-00130-7","article-title":"Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy","volume":"4","author":"Recondo","year":"2020","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib40","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3390\/jpm12050750","article-title":"FFPE-based NGS approaches into clinical practice: the limits of glory from a pathologist viewpoint","volume":"12","author":"Cappello","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.jtho.2025.07.009_bib41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/his.15078","article-title":"Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists","volume":"84","author":"Kerr","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.jtho.2025.07.009_bib42","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.5858\/arpa.2019-0009-SA","article-title":"Preanalytics and precision pathology: pathology practices to ensure molecular integrity of cancer patient biospecimens for precision medicine","volume":"143","author":"Compton","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2025.07.009_bib43","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/002215549904700512","article-title":"Effect of bone decalcification procedures on DNA in situ hybridization and comparative genomic hybridization. EDTA is highly preferable to a routinely used acid decalcifier","volume":"47","author":"Alers","year":"1999","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.jtho.2025.07.009_bib44","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/bjc.2013.416","article-title":"Technical and implementation issues in using next-generation sequencing of cancers in clinical practice","volume":"109","author":"Ulahannan","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2025.07.009_bib45","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-23-3321","article-title":"Measurement of ctDNA tumor fraction identifies informative negative liquid biopsy results and informs value of tissue confirmation","volume":"30","author":"Rolfo","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.07.009_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2024.100221","article-title":"Liquid biopsy detection of gene Copy Number (CN) losses including existing and emerging clinical targets","volume":"5","author":"Rolfo","year":"2024","journal-title":"J Liq Biopsy"},{"key":"10.1016\/j.jtho.2025.07.009_bib47","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: A consensus statement from the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib48","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jtho.2019.11.024","article-title":"Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression","volume":"15","author":"Aldea","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib49","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma","volume":"6","author":"De Mattos-Arruda","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.07.009_bib50","first-page":"1599","article-title":"Clonal hematopoiesis and risk for hematologic malignancy","volume":"136","author":"Warren","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2025.07.009_bib51","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2025.07.009_bib52","article-title":"Liquid biopsies for circulating tumor DNA detection may reveal occult hematologic malignancies in patients with solid tumors","volume":"7","author":"Aldea","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib53","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1158\/1078-0432.CCR-18-0143","article-title":"False-positive plasma genotyping due to clonal hematopoiesis","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2025.07.009_bib54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41698-024-00544-7","article-title":"Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients","volume":"8","author":"Vasseur","year":"2024","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib55","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13073-019-0688-9","article-title":"Is \u2018likely pathogenic\u2019 really 90% likely? Reclassification data in ClinVar","volume":"11","author":"Harrison","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.jtho.2025.07.009_bib56","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib57","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib58","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/annonc\/mdz036","article-title":"Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"30","author":"Condorelli","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib59","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtho.2024.03.016","article-title":"Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review","volume":"19","author":"Borgeaud","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2021.102080","article-title":"Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes","volume":"76","author":"John","year":"2022","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.jtho.2025.07.009_bib61","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"issue":"suppl 16","key":"10.1016\/j.jtho.2025.07.009_bib62","doi-asserted-by":"crossref","first-page":"TPS8666","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8666","article-title":"FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002)","volume":"42","author":"Le","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib63","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nature23291","article-title":"Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS","volume":"548","author":"Yao","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2025.07.009_bib64","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/2159-8290.CD-24-0417","article-title":"Pan-cancer analysis of oncogenic MET fusions reveals distinct pathogenomic subsets with differential sensitivity to MET-targeted therapy","volume":"15","author":"Febres-Aldana","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.07.009_bib65","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-24-1726","article-title":"Antitumor activity of vebreltinib and characterization of clinicogenomic features in solid tumors with MET rearrangements","volume":"15","author":"Nakazawa","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2025.07.009_bib66","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtho.2020.10.156","article-title":"Potential unreliability of uncommon ALK, ROS1, and RET genomic breakpoints in predicting the efficacy of targeted therapy in NSCLC","volume":"16","author":"Li","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib67","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.jtho.2025.07.009_bib68","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoto.2015.3270","article-title":"Role of CRTC1\/MAML2 translocation in the prognosis and clinical outcomes of mucoepidermoid carcinoma","volume":"142","author":"Saade","year":"2016","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jtho.2025.07.009_bib69","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199801153380303","article-title":"SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma","volume":"338","author":"Kawai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2025.07.009_bib70","article-title":"Opposing roles of SPOP mutations in human prostate and endometrial cancers","volume":"7","author":"Cavalcante","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib71","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/ng0594-85","article-title":"Mutations of the VHL tumour suppressor gene in renal carcinoma","volume":"7","author":"Gnarra","year":"1994","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2025.07.009_bib72","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.annonc.2021.09.002","article-title":"Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients","volume":"32","author":"Aldea","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib73","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jtho.2024.11.016","article-title":"Differentiating separate primary lung adenocarcinomas from intrapulmonary metastases with emphasis on pathological and molecular considerations: recommendations from the International Association for the Study of Lung Cancer pathology committee","volume":"20","author":"Chou","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib74","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jtho.2023.09.275","article-title":"Genomic staging of multifocal lung squamous cell carcinomas is independent of the comprehensive morphologic assessment","volume":"19","author":"Dacic","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100453","article-title":"Pathologic assessment and staging of multiple non-small cell lung carcinomas: A paradigm shift with the emerging role of molecular methods","volume":"37","author":"Chang","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2025.07.009_bib76","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/annonc\/mdz136","article-title":"Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group","volume":"30","author":"Mandelker","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib77","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00328","article-title":"Identification of incidental germline mutations in patients with advanced solid tumors who underwent cell-free circulating tumor DNA sequencing","volume":"36","author":"Slavin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2025.07.009_bib78","doi-asserted-by":"crossref","first-page":"v103","DOI":"10.1093\/annonc\/mdw327","article-title":"Prevention and screening in BRCA mutation carriers and other breast\/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening","volume":"27","author":"Paluch-Shimon","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib79","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkw520","article-title":"FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing","volume":"44","author":"Shen","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jtho.2025.07.009_bib80","doi-asserted-by":"crossref","first-page":"16910","DOI":"10.1073\/pnas.1009843107","article-title":"Allele-specific copy number analysis of tumors","volume":"107","author":"Van Loo","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.07.009_bib81","doi-asserted-by":"crossref","first-page":"20007","DOI":"10.1073\/pnas.0710052104","article-title":"Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma","volume":"104","author":"Beroukhim","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2025.07.009_bib82","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13029-016-0060-z","article-title":"PureCN: copy number calling and SNV classification using targeted short read sequencing","volume":"11","author":"Riester","year":"2016","journal-title":"Source Code Biol Med"},{"key":"10.1016\/j.jtho.2025.07.009_bib83","article-title":"Inference of germline mutational status and evaluation of loss of heterozygosity in high-depth, tumor-only sequencing data","volume":"2018","author":"Khiabanian","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib84","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1200\/JCO.23.00580","article-title":"Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer","volume":"42","author":"Ricciuti","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib85","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","article-title":"PL02.11 normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-lung 01","volume":"19","author":"Garassino","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2025.07.009_bib86","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","volume":"31","author":"Yoo","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2025.07.009_bib87","doi-asserted-by":"crossref","first-page":"7304","DOI":"10.1038\/s41467-021-27358-6","article-title":"Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset","volume":"12","author":"Kehl","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2025.07.009_bib88","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41746-024-01233-2","article-title":"Privacy-preserving large language models for structured medical information retrieval","volume":"7","author":"Wiest","year":"2024","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.jtho.2025.07.009_bib89","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41586-024-08167-5","article-title":"Automated real-world data integration improves cancer outcome prediction","volume":"636","author":"Jee","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2025.07.009_bib90","author":"Brixi"},{"key":"10.1016\/j.jtho.2025.07.009_bib91","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-025-00991-6","article-title":"Development and validation of an autonomous artificial intelligence agent for clinical decision-making in oncology [e-pub ahead of print]","author":"Ferber","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jtho.2025.07.009_bib92","doi-asserted-by":"crossref","DOI":"10.1056\/AIcs2300191","article-title":"GPT-4 in a Cancer Center \u2014 institute-wide deployment challenges and lessons learned","volume":"1","author":"Umeton","year":"2024","journal-title":"NEJM AI"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425008317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086425008317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:26:18Z","timestamp":1793499978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086425008317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":91,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1556086425008317"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2025.07.009","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2025.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}